Title of article
The Role of Hemoperfusion in COVID-19 Infection: A Case Series
Author/Authors
Amirsavadkouhi ، Ali Chairman of Iranian Critical Care Society - Mehrad Hospital , Jahangirifard ، Alireza Chronic Respiratory Disease Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD) - Shahid Beheshti University of Medical Sciences , Shahrami ، Reza Health and Family Research Center - National Iranian Oil Company (NIOC) Hospital , Safari ، Saeid Functional Neurosurgery Research Center, Shohada Tajrish Comprehensive Neurosurgical Center of Excellence - Shahid Beheshti University of Medical Sciences , Feizabadi ، Faezeh Department of Clinical Pharmacy - School of Pharmacy - Shahid Beheshti University of Medical Sciences , Mirshafiei Langari ، Zahra Chronic Respiratory Disease Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD) - Shahid Beheshti University of Medical Sciences , Dastan ، Alireza Ernest and Julio Gallo Management Program - School of Engineering - University of California , Mirtajani ، Bashir Lung transplant Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD) - Shahid Beheshti University of Medical Sciences , Ghaznavi ، Shayan Noor Afshar Hospital , Dastan ، Farzaneh Department of Clinical Pharmacy - Chronic Respiratory Disease Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), School of Pharmacy - Shahid Beheshti University of Medical Sciences
From page
189
To page
194
Abstract
The rapid expansion of a novel human infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved into a pandemic, affecting thousands of people world wild. Some patients with coronavirus disease 2019 (COVID-19) develop severe infection, which may progress to acute respiratory distress syndrome, multiple organ failure, and death. Increasing studies indicate that abnormal elevation of cytokine levels in response to SARS-CoV-2 may contribute to the pathological process that leads mortality of COVID-19. Thus, application of extracorporeal hemoperfusion (HP) for removal of excessive cytokines from the blood can potentially mitigate or reverse cytokine storm related complications of COVID-19. Here, we presented series of COVID-19 patients, who were treated with HP (HA 380 cartridge, Jafron Biomedocal Co, China). The medical records were evaluated retrospectively to determine the effect of HP on patients’ clinical outcome. Our results showed that HP improvee PO2 and O2 saturation in patients with severe COVID-19. After the last courses of HP, 5 out of 6 patients were extubated and transferred to the general ward with an acceptable medical condition. The following case series demonstrate the promising role of HP in controlling the consequential effect of cytokine storm following a COVID-19 infection, which could facilitate patient survival.
Keywords
Coronavirus disease 2019 , Hemoperfusion , Acute respiratory distress syndrome
Journal title
Archives of Anesthesiology and Critical Care
Journal title
Archives of Anesthesiology and Critical Care
Record number
2667795
Link To Document